Kenya - English - Pharmacy and Poisons Board

regal pharmaceuticals limited regal pharmaceuticals limited 7879/18 off baba - salbutamol (as sulphate ) - syrup - salbumol syrup - adrenergics for systemic use: selective

Philippines - English - FDA (Food And Drug Administration)

penta labs australia (philippines) - salbutamol (as sulfate) - syrup - 2mg / 5ml

Bangladesh - English - DGDA (Directorate General of Drug Administration)

indo-bangla pharmaceuticals ltd. - salbutamol - tablet - 2 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

indo-bangla pharmaceuticals ltd. - salbutamol - syrup - 2 mg/5 ml

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

regal pharmaceuticals limited, kenya - salbutamol - syrup - 2mg/5ml

Uganda - English - National Drug Authority

regal pharmaceuicals ltd - salbutamol - oral liquid ordinary syrups - 2mg/5ml

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - salbutamol sulfate 29.64mg equivalent to salbutamol 100 µg/actuation (200 doses);   - aerosol inhaler, metered dose - 100 mcg/dose - active: salbutamol sulfate 29.64mg equivalent to salbutamol 100 µg/actuation (200 doses)   excipient: ethanol norflurane - salbutamol provides short-acting (4 hour) bronchodilation with fast onset (within 5 minutes) in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. it is suitable for long-term use in the relief and prevention of asthmatic symptoms. salamol cfc-free inhaler should be used to relieve symptoms when they occur and to prevent them in those circumstances recognised by the patient to precipitate an asthmatic attack (e.g. before exercise or unavoidable allergen exposure).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - salbutamol sulfate, quantity: 120.5 microgram/actuation (equivalent: salbutamol, qty 100 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - other conditions: do not puncture or incinerate even when empty as canister may explode. for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 120.5 microgram/actuation (equivalent: salbutamol, qty 100 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - other conditions: do not puncture or incinerate even when empty as canister may explode. indications: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 120.5 microgram/actuation (equivalent: salbutamol, qty 100 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - other conditions: do not puncture or incinerate even when empty as canister may explode. indications: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.